Kato, Shumei

Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers

Goodman, A. M., Kato, S., Bazhenova, L., Patel, S. P., Frampton, G. M., Miller, V., Stephens, P. J., Daniels, G. A., & Kurzrock, R. (2017) · Molecular Cancer Therapeutics

Cancer Immunotherapy and BiomarkersCancer Genomics and Diagnostics

Cited by 2,264

An integrin β3-KRAS-RalB complex drives tumour stemness and resistance to EGFR inhibition

Seguin, L., Kato, S., Franovic, A., Camargo, M. F., Lesperance, J., Elliott, K. C., Yebra, M., Mielgo, A., Lowy, A. M., Husain, H., et al. (2014) · Nature Cell Biology

Cancer Cells and MetastasisCell Adhesion Molecules Research

Cited by 374

Analysis of NTRK Alterations in Pan-Cancer Adult and Pediatric Malignancies: Implications for NTRK-Targeted Therapeutics

Okamura, R., Boichard, A., Kato, S., Sicklick, J. K., Bazhenova, L., & Kurzrock, R. (2018) · JCO Precision Oncology

Cancer Genomics and DiagnosticsCancer Mechanisms and Therapy

Cited by 328

Targeting ARID1A mutations in cancer

Mullen, J., Kato, S., Sicklick, J. K., & Kurzrock, R. (2021) · Cancer Treatment Reviews

Chromatin Remodeling and CancerOvarian cancer diagnosis and treatment

Cited by 186

Genomic Assessment of Blood-Derived Circulating Tumor DNA in Patients With Colorectal Cancers: Correlation With Tissue Sequencing, Therapeutic Response, and Survival

Kato, S., Schwaederlé, M. C., Fanta, P. T., Okamura, R., Leichman, L., Lippman, S. M., Lanman, R. B., Raymond, V. M., Talasaz, A., & Kurzrock, R. (2019) · JCO Precision Oncology

Cancer Genomics and DiagnosticsColorectal Cancer Treatments and Studies

Cited by 52